Compare TG Therapeutics Inc (TGTX) vs TeraWulf Inc (WULF) Price & Performance

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.

WULF trades at $17.19, up 6.11% today amid a broader neocloud sector rally. The stock shows bearish technical signals with negative earnings trends, posting significant losses in recent quarters. Despite strong analyst consensus (14 buy ratings, 0 hold/sell), fundamental metrics reveal challenges with a P/S of 43.81, P/B of 56.71, and deeply negative profit margins. Recent news highlights the company's pivot to high-performance computing with a major Anthropic deal and 102 MW of operational capacity.

The outlook remains speculative with high execution risks and substantial capital requirements. While analyst price targets average $38.00 (121% upside potential), investors face volatility from ongoing losses, construction cost pressures, and regulatory exposure to New York's data-center moratorium. The stock's performance will depend on successful HPC expansion and profitability improvements.